# US 12,766,106 B2 · Microparticles containing moxidectin, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,766,106 B2
- Document ID: US12766106B2
- Status: Granted
- Kind: B2
- Application number: 18/434,686
- Filed: 2024-02-06
- Published: 2024-07-18
- Granted: 2026-10-20
- Earliest claimed: 2017-09-06
- Assignees: Inventage Lab Inc.
- Applicants: Inventage Lab Inc.
- Inventors: Ju Hee Kim
- Web page: https://patentgrep.com/patent/US12766106B2

## CPC

- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/365: Lactones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 45-130 μm, depending on the type of polymer. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.

## Claims

### Claim 1

Microparticles comprising moxidectin and polylactide (PLA),
wherein,
the moxidectin is uniformly distributed in spherical PLA microparticles,
the microparticles have an average particle diameter of 45 to 120 μm,
the PLA and the moxidectin are present at a weight ratio of 9:1,
the microparticles reach at least 80% cumulative release of moxidectin in 30 to 54 hours, and
the microparticles are configured to continuously release the moxidectin drug for 3 to 6 months after administering the microparticles.

### Claim 2 (depends on 1)

The microparticles comprising moxidectin of claim 1, wherein the microparticles are prepared by using a microchannel, and a width (w) of a cross section of the channel is within a ratio range of 0.7 to 1.3 for an average diameter (d′) of the microparticles.

### Claim 3 (depends on 1)

The microparticles comprising moxidectin of claim 1, wherein the microparticles are prepared by using a microchannel, and a height (d) of a cross section of the channel is within a ratio range of 0.7 to 1.3 for an average diameter (d′) of the microparticles.

### Claim 4 (depends on 1)

A pharmaceutical composition for treatment of heartworm disease, comprising the microparticles according to claim 1.